Wedbush reiterated their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research note published on Wednesday morning, Benzinga reports. Wedbush currently has a $152.00 target price on the stock. NBIX has been the topic of a number of other research reports. Canaccord Genuity Group lifted their price target on shares […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) were down 5.3% on Wednesday . The stock traded as low as $132.58 and last traded at $133.02. Approximately 153,432 shares were traded during trading, a decline of 81% from the average daily volume of 812,679 shares. The stock had previously closed at $140.48. Analyst […]
Westfield Capital Management Co. LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 594,437 shares of the company’s stock after selling 54,855 shares during the period. Westfield Capital Management Co. LP […]
Great Lakes Advisors LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 163,485 shares of the company’s stock after purchasing an additional 1,528 shares during the period. Great Lakes Advisors LLC owned about 0.17% […]
Russell Investments Group Ltd. Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Rating of "Moderate Buy" by Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective cut by JPMorgan Chase & Co. from $154.00 to $148.00 in a report published on Friday, Benzinga reports. They currently have an overweight rating on the stock. Several other research analysts have also weighed in on the stock. Raymond James upped their price objective on […]
TD Cowen 44th Annual Healthcare Conference on March 5 in Boston
Leerink Partners Global Biopharma Conference on March 12 in Miami
Barclays 26th Annual Global Healthcare Conference on March 13 in...
WINTON GROUP Ltd grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 68.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,272 shares of the company’s stock after acquiring an additional 1,738 shares during the period. WINTON GROUP Ltd’s […]